File Download
  • No File Attached
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer
  • Basic View
  • Metadata View
  • XML View
TitleCharacterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer
 
AuthorsCheung, KF2
Lam, CNY3
Wu, K1
Ng, EKO3
Chong, WWS2
Cheng, ASL3
To, KF3
Fan, D1
Sung, JJY2
Yu, J2
 
Keywordsdiagnosis
epigenetic alteration
gastric cancer
prognosis
ring finger protein 180
 
Issue Date2012
 
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
 
CitationCancer, 2012, v. 118 n. 4, p. 947-959 [How to Cite?]
DOI: http://dx.doi.org/10.1002/cncr.26189
 
AbstractBackground: By using genome-wide methylation screening, the authors identified ring finger protein 180 (RNF180) as preferentially methylated in cancer. This study was undertaken to clarify its structure and functional role in gastric cancer. Methods: The transcription start site and core functional promoter region of RNF180 were revealed by 5â rapid amplification of cDNA ends and luciferase activity assays. Promoter methylation was detected by combined bisulfite restriction analysis and bisulfite genomic sequencing. Cell growth was detected by colony formation assay, apoptosis by annexin V assay, and RNF180 target genes by cDNA microarray. Results: The authors revealed the transcription start site of RNF180 gene and identified the functional core promoter region (-202/+372) in the CpG island, which could be silenced by in vitro methylation assay. RNF180 was silenced in 6 of 7 gastric cancer cell lines and significantly down-regulated in primary gastric cancers compared with adjacent normal tissues (P =.001). Loss of gene expression was associated with promoter methylation. Re-expression of RNF180 suppressed cell growth (P <.001) and induced apoptosis (P <.05), which were mediated by up-regulating the antiproliferation regulators MTSS1 and CDKN2A and the proapoptotic mediator TIMP3. Promoter methylation of RNF180 was detected in 76% (150 of 198) of primary gastric cancers and 55% (11 of 20) of intestinal metaplasia, but in none of 23 normal gastric tissues. Methylated RNF180 DNA was detected in the plasma of 56% of gastric cancer patients, but not in healthy controls (P =.003). Patients with low or loss of RNF180 expression had significantly poorer overall survival. Conclusions: RNF180 is a novel potential tumor suppressor in gastric carcinogenesis and has potential clinical utility as a biomarker for gastric cancer patients. © 2011 American Cancer Society.
 
ISSN0008-543X
2012 Impact Factor: 5.201
2012 SCImago Journal Rankings: 2.407
 
DOIhttp://dx.doi.org/10.1002/cncr.26189
 
ISI Accession Number IDWOS:000299834300012
Funding AgencyGrant Number
Research Grants Council473008
973 national program2010CB529305
RFCID08070172
Chinese University of Hong Kong Group3110043
Chinese University of Hong Kong1903026
Funding Information:

The project was supported by a Research Grants Council grant (473008), a 973 national program fund (2010CB529305), an RFCID (08070172), a Chinese University of Hong Kong Group Research Scheme (3110043), and a Chinese University of Hong Kong Focused Investments Scheme (1903026).

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorCheung, KF
 
dc.contributor.authorLam, CNY
 
dc.contributor.authorWu, K
 
dc.contributor.authorNg, EKO
 
dc.contributor.authorChong, WWS
 
dc.contributor.authorCheng, ASL
 
dc.contributor.authorTo, KF
 
dc.contributor.authorFan, D
 
dc.contributor.authorSung, JJY
 
dc.contributor.authorYu, J
 
dc.date.accessioned2011-08-26T14:27:53Z
 
dc.date.available2011-08-26T14:27:53Z
 
dc.date.issued2012
 
dc.description.abstractBackground: By using genome-wide methylation screening, the authors identified ring finger protein 180 (RNF180) as preferentially methylated in cancer. This study was undertaken to clarify its structure and functional role in gastric cancer. Methods: The transcription start site and core functional promoter region of RNF180 were revealed by 5â rapid amplification of cDNA ends and luciferase activity assays. Promoter methylation was detected by combined bisulfite restriction analysis and bisulfite genomic sequencing. Cell growth was detected by colony formation assay, apoptosis by annexin V assay, and RNF180 target genes by cDNA microarray. Results: The authors revealed the transcription start site of RNF180 gene and identified the functional core promoter region (-202/+372) in the CpG island, which could be silenced by in vitro methylation assay. RNF180 was silenced in 6 of 7 gastric cancer cell lines and significantly down-regulated in primary gastric cancers compared with adjacent normal tissues (P =.001). Loss of gene expression was associated with promoter methylation. Re-expression of RNF180 suppressed cell growth (P <.001) and induced apoptosis (P <.05), which were mediated by up-regulating the antiproliferation regulators MTSS1 and CDKN2A and the proapoptotic mediator TIMP3. Promoter methylation of RNF180 was detected in 76% (150 of 198) of primary gastric cancers and 55% (11 of 20) of intestinal metaplasia, but in none of 23 normal gastric tissues. Methylated RNF180 DNA was detected in the plasma of 56% of gastric cancer patients, but not in healthy controls (P =.003). Patients with low or loss of RNF180 expression had significantly poorer overall survival. Conclusions: RNF180 is a novel potential tumor suppressor in gastric carcinogenesis and has potential clinical utility as a biomarker for gastric cancer patients. © 2011 American Cancer Society.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationCancer, 2012, v. 118 n. 4, p. 947-959 [How to Cite?]
DOI: http://dx.doi.org/10.1002/cncr.26189
 
dc.identifier.doihttp://dx.doi.org/10.1002/cncr.26189
 
dc.identifier.eissn1097-0142
 
dc.identifier.epage959
 
dc.identifier.hkuros191077
 
dc.identifier.isiWOS:000299834300012
Funding AgencyGrant Number
Research Grants Council473008
973 national program2010CB529305
RFCID08070172
Chinese University of Hong Kong Group3110043
Chinese University of Hong Kong1903026
Funding Information:

The project was supported by a Research Grants Council grant (473008), a 973 national program fund (2010CB529305), an RFCID (08070172), a Chinese University of Hong Kong Group Research Scheme (3110043), and a Chinese University of Hong Kong Focused Investments Scheme (1903026).

 
dc.identifier.issn0008-543X
2012 Impact Factor: 5.201
2012 SCImago Journal Rankings: 2.407
 
dc.identifier.issue4
 
dc.identifier.openurl
 
dc.identifier.pmid21717426
 
dc.identifier.scopuseid_2-s2.0-84856804279
 
dc.identifier.spage947
 
dc.identifier.urihttp://hdl.handle.net/10722/137554
 
dc.identifier.volume118
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
 
dc.publisher.placeUnited States
 
dc.relation.ispartofCancer
 
dc.relation.referencesReferences in Scopus
 
dc.rightsCancer. Copyright © John Wiley & Sons, Inc.
 
dc.subject.meshApoptosis - genetics - physiology
 
dc.subject.meshCell Line, Tumor
 
dc.subject.meshCell Proliferation
 
dc.subject.meshDNA, Neoplasm - blood - genetics
 
dc.subject.meshStomach Neoplasms - genetics - mortality - physiopathology
 
dc.subjectdiagnosis
 
dc.subjectepigenetic alteration
 
dc.subjectgastric cancer
 
dc.subjectprognosis
 
dc.subjectring finger protein 180
 
dc.titleCharacterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Cheung, KF</contributor.author>
<contributor.author>Lam, CNY</contributor.author>
<contributor.author>Wu, K</contributor.author>
<contributor.author>Ng, EKO</contributor.author>
<contributor.author>Chong, WWS</contributor.author>
<contributor.author>Cheng, ASL</contributor.author>
<contributor.author>To, KF</contributor.author>
<contributor.author>Fan, D</contributor.author>
<contributor.author>Sung, JJY</contributor.author>
<contributor.author>Yu, J</contributor.author>
<date.accessioned>2011-08-26T14:27:53Z</date.accessioned>
<date.available>2011-08-26T14:27:53Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Cancer, 2012, v. 118 n. 4, p. 947-959</identifier.citation>
<identifier.issn>0008-543X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/137554</identifier.uri>
<description.abstract>Background: By using genome-wide methylation screening, the authors identified ring finger protein 180 (RNF180) as preferentially methylated in cancer. This study was undertaken to clarify its structure and functional role in gastric cancer. Methods: The transcription start site and core functional promoter region of RNF180 were revealed by 5&#226; rapid amplification of cDNA ends and luciferase activity assays. Promoter methylation was detected by combined bisulfite restriction analysis and bisulfite genomic sequencing. Cell growth was detected by colony formation assay, apoptosis by annexin V assay, and RNF180 target genes by cDNA microarray. Results: The authors revealed the transcription start site of RNF180 gene and identified the functional core promoter region (-202/+372) in the CpG island, which could be silenced by in vitro methylation assay. RNF180 was silenced in 6 of 7 gastric cancer cell lines and significantly down-regulated in primary gastric cancers compared with adjacent normal tissues (P =.001). Loss of gene expression was associated with promoter methylation. Re-expression of RNF180 suppressed cell growth (P &lt;.001) and induced apoptosis (P &lt;.05), which were mediated by up-regulating the antiproliferation regulators MTSS1 and CDKN2A and the proapoptotic mediator TIMP3. Promoter methylation of RNF180 was detected in 76% (150 of 198) of primary gastric cancers and 55% (11 of 20) of intestinal metaplasia, but in none of 23 normal gastric tissues. Methylated RNF180 DNA was detected in the plasma of 56% of gastric cancer patients, but not in healthy controls (P =.003). Patients with low or loss of RNF180 expression had significantly poorer overall survival. Conclusions: RNF180 is a novel potential tumor suppressor in gastric carcinogenesis and has potential clinical utility as a biomarker for gastric cancer patients. &#169; 2011 American Cancer Society.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc. The Journal&apos;s web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741</publisher>
<relation.ispartof>Cancer</relation.ispartof>
<rights>Cancer. Copyright &#169; John Wiley &amp; Sons, Inc.</rights>
<subject>diagnosis</subject>
<subject>epigenetic alteration</subject>
<subject>gastric cancer</subject>
<subject>prognosis</subject>
<subject>ring finger protein 180</subject>
<subject.mesh>Apoptosis - genetics - physiology</subject.mesh>
<subject.mesh>Cell Line, Tumor</subject.mesh>
<subject.mesh>Cell Proliferation</subject.mesh>
<subject.mesh>DNA, Neoplasm - blood - genetics</subject.mesh>
<subject.mesh>Stomach Neoplasms - genetics - mortality - physiopathology</subject.mesh>
<title>Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1097-0142 (Electronic) 0008-543X (Linkin&amp;volume=&amp;spage=&amp;epage=&amp;date=2011&amp;atitle=Characterization+of+the+gene+structure,+functional+significance,+and+clinical+application+of+RNF180,+a+novel+gene+in+gastric+cancer</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1002/cncr.26189</identifier.doi>
<identifier.pmid>21717426</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84856804279</identifier.scopus>
<identifier.hkuros>191077</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-84856804279&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>118</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>947</identifier.spage>
<identifier.epage>959</identifier.epage>
<identifier.eissn>1097-0142</identifier.eissn>
<identifier.isi>WOS:000299834300012</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. Xijing Hospital
  2. Prince of Wales Hospital Hong Kong
  3. Chinese University of Hong Kong